Market Monitor chemicals Indonesia 2018

マーケットモニター

  • インドネシア
  • 化学・薬品

19 7 2018

Indonesian pharmaceuticals sector growth is driven by a rising population and the roll-out of the government's universal healthcare insurance system.

 

 

 

 

 

 

Indonesia chemicals 2018 pic1

  • The Indonesian pharmaceuticals sector value added grew 7.1% in 2017, and in 2018 an increase of about 7.5% is expected, driven by a rising population and roll-out of the government's universal healthcare insurance system, which will expand access to medicine and healthcare.
  • Foreign pharmaceutical businesses dominate the market for patented drugs, and have invested more than USD 1 billion to build factories and in clinical research. However, foreign players continue to face significant competition from domestic companies like Kalbe Farma, Tempo Scan Pacific and Kimia Farma. Those local firms are well established with significant activity across various subsectors, including logistics, consumer healthcare and prescription drugs.
  • Due to the recent currency depreciation we expect the profit margins of manufacturers to deteriorate in the coming months, as a large percentage of raw materials for pharmaceutical production has to be imported. However, the impact should be partly mitigated by higher sales prices.
  • In general, banks are willing to lend to the sector due to the positive performance trend and growth prospects. Gearing tends to be generally lower in manufacturing, but higher in the distribution segment, due to working capital purposes.

  • On average, payments in the Indonesian pharmaceuticals sector take 30-60 days. The number of non-payment notifications and insolvencies was low in 2017, and no substantial increase is expected in 2018. Due to this and the favourable growth prospects our underwriting approach to the pharmaceuticals sector is generally positive.

  • Our underwriting stance for the basic chemicals and petrochemical subsectors is neutral. Petrochemicals has developed only slowly in recent years, with most players lacking value chain integration (i.e. operating in either the upstream segment or the downstream segment only). While basic chemicals show stable growth rates (mainly driven by construction, automotive, increased urbanization and a growing middle class), inefficiencies and red tape remain stumbling blocks.

 

 

関連ドキュメント

免責条項

本ウェブサイトの記載事項は、一般的な情報提供のみを目的とし、何らの目的においてもこれに依拠すべきではありません。規定条件については、実際の保険契約または該当の製品・サービス契約をご覧ください。本ウェブサイトの記載事項は、買主についてのまたは利用者の代理人としてのデューデリジェンスの実施義務を含め、アトラディウス側に何らの権利、義務または責任を生じさせるものではありません。アトラディウスが買主についてデューデリジェンスを実施する場合は、当社の保険引受をその目的とし、被保険者その他の利益を目的とするものではありません。さらに、アトラディウスおよびその関連会社、系列会社、子会社は、本ウェブサイトの掲載情報の利用によって生じた直接的、間接的、特異的、付随的、結果的損害について一切の責任を負いません。